Abstract
Characterization of epigenetic events in carcinogenesis has led to the discovery of a new class of oncogenes and thereby a new class of therapeutic targets. Among the new therapeutic approaches are modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). HDACs deacetylate histones as well as transcription factors and can modulate gene expression through both these mechanisms in normal and malignant cells. Furthermore, acetylation is an important posttranslational modulation of several proteins involved in the regulation of cell proliferation, differentiation and apoptosis in normal as well as cancer cells. Even though several HDAC inhibitors have been characterized in vitro, only a limited number of these agents are in clinical trials. Various HDAC inhibitors differ in their toxicity profile when comparing the side effects described in the available clinical studies of HDAC inhibition in the treatment of cancer. These drugs may also affect normal hematopoiesis; hematologic toxicity is common to many drugs but stimulation of hematopoiesis seems to occur for others. HDAC inhibitors usually affect < 10% of the genes in cancer cells. Divergent effects of HDAC inhibition on the global gene expression profiles have been described when testing various cancer cells, and this is further complicated by altered HDAC expression induced by HDAC inhibitors. However, increased p21 expression seems to be a common characteristic for most studies, suggesting an important role of this molecule during HDAC inhibitory treatment. Even though the initial studies are encouraging, additional in vitro and in vivo pharmacological characterization is definitely needed.
Keywords: Cancer, Protein acetylation, Histone deacetylase
Current Pharmaceutical Biotechnology
Title: Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Volume: 8 Issue: 6
Author(s): O. Bruserud, C. Stapnes, E. Ersvær, B. T. Gjertsen and A. Ryningen
Affiliation:
Keywords: Cancer, Protein acetylation, Histone deacetylase
Abstract: Characterization of epigenetic events in carcinogenesis has led to the discovery of a new class of oncogenes and thereby a new class of therapeutic targets. Among the new therapeutic approaches are modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). HDACs deacetylate histones as well as transcription factors and can modulate gene expression through both these mechanisms in normal and malignant cells. Furthermore, acetylation is an important posttranslational modulation of several proteins involved in the regulation of cell proliferation, differentiation and apoptosis in normal as well as cancer cells. Even though several HDAC inhibitors have been characterized in vitro, only a limited number of these agents are in clinical trials. Various HDAC inhibitors differ in their toxicity profile when comparing the side effects described in the available clinical studies of HDAC inhibition in the treatment of cancer. These drugs may also affect normal hematopoiesis; hematologic toxicity is common to many drugs but stimulation of hematopoiesis seems to occur for others. HDAC inhibitors usually affect < 10% of the genes in cancer cells. Divergent effects of HDAC inhibition on the global gene expression profiles have been described when testing various cancer cells, and this is further complicated by altered HDAC expression induced by HDAC inhibitors. However, increased p21 expression seems to be a common characteristic for most studies, suggesting an important role of this molecule during HDAC inhibitory treatment. Even though the initial studies are encouraging, additional in vitro and in vivo pharmacological characterization is definitely needed.
Export Options
About this article
Cite this article as:
Bruserud O., Stapnes C., Ersvær E., Gjertsen T. B. and Ryningen A., Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells, Current Pharmaceutical Biotechnology 2007; 8 (6) . https://dx.doi.org/10.2174/138920107783018417
DOI https://dx.doi.org/10.2174/138920107783018417 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ
Current Vascular Pharmacology Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Clonidine in Perioperative Medicine and Intensive Care Unit: More Than An Anti-Hypertensive Drug
Current Drug Targets Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Thoracic Surgical Approaches in the Trauma Setting: A Basic Review
Current Respiratory Medicine Reviews Angiotensin, The Hormone to be Blocked by Antithypertensive Drugs, and Perhaps Why They Dont Work
Current Vascular Pharmacology Levosimendan for Heart-Operated Patients: What is the State of the Art?
Recent Patents on Cardiovascular Drug Discovery Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Citric Acid: A Green Bioorganic Catalyst for One-Pot Three-Component Synthesis of 2,3-dihydroquinazoline-4 (1H)-ones
Current Organocatalysis Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy